Probiotic Therapies in Inflammatory Bowel Disease

Inflammatory bowel disease (IBD), encompassing ulcerative colitis and Crohn’s disease, arises from complex interactions among genetic predisposition, the immune system and the gut microbiota. Probiotic therapies aim to restore microbial balance by delivering live beneficial microorganisms to the intestinal tract. These agents may act through several mechanisms: competitive exclusion of pathogens, enhancement of epithelial barrier integrity, modulation of mucosal immune responses and production of health‐promoting metabolites such as short‐chain fatty acids. Single‐strain preparations, multi‐species consortia and synbiotic combinations (probiotics plus prebiotics) have all been explored. In preclinical models, specific Lactobacillus and Bifidobacterium strains reduce mucosal inflammation by downregulating proinflammatory cytokine cascades and reinforcing tight junction proteins. Clinically, probiotic regimens have shown promise in maintaining remission in ulcerative colitis and in reducing postoperative recurrence in Crohn’s disease, though results remain heterogeneous. Factors influencing efficacy include strain selection, dosage, formulation, treatment duration and patient‐specific variables such as diet and genetic background. Emerging approaches integrate probiotics with dietary fibres, polyphenols or postbiotic compounds to enhance mucosal resilience. Ongoing large‐scale trials are refining optimal regimens, while advances in microbiome sequencing and metabolomics promise to personalise probiotic therapy and improve long‐term outcomes for patients worldwide.

Research from Nature Portfolio

No recent Nature Portfolio content available.

Probiotic Therapies in Inflammatory Bowel Disease publication trend

The graph below shows the total number of articles in probiotic therapies in inflammatory bowel disease across all publications each year (not limited to Nature Index journals).

Technical terms

Inflammatory Bowel Disease (IBD): Chronic inflammatory disorders of the gastrointestinal tract, mainly ulcerative colitis and Crohn’s disease.

Probiotics: Live microorganisms which, when administered in adequate amounts, confer a health benefit on the host.

Prebiotics: Non‐digestible substrates selectively utilised by beneficial gut microbes to promote host health.

Synbiotics: Formulations combining probiotics and prebiotics to synergistically enhance microbial function.

Gut Microbiota: The community of microorganisms residing in the gastrointestinal tract, crucial for digestion, immunity and mucosal integrity.

Dysbiosis: An imbalance in the composition or function of the gut microbiota associated with disease.

Tight Junction Proteins: Components of the epithelial barrier (e.g. occludin, claudins, ZO-1) that regulate permeability and prevent pathogen translocation.

References

1. Ulcerative colitis: molecular insights and intervention therapy. Molecular Biomedicine (2024).
2. The development of probiotics and prebiotics therapy to ulcerative colitis: a therapy that has gained considerable momentum. Cell Communication and Signaling (2024).
3. Protective effect of synbiotic combination of Lactobacillus plantarum SC-5 and olive oil extract tyrosol in a murine model of ulcerative colitis. Journal of Translational Medicine (2024).